TRARESA: A tissue microarray-based hospital system for biomarker validation and discovery

Pathology

Volumn 40, Issue 5, 2008, Pages 441-449

  Das, Kakoli ^a   Mohd Omar, Mohd Feroz ^a   Ong, Chee Wee ^a   Bin Abdul Rashid, Suhaimi ^a   Peh, Bee Keow ^a   Putti, Thomas Choudary ^a   Tan, Puay Hoon ^b   Chia, Kee Seng ^a   Teh, Ming ^a   Shah, Nilesh ^a   Soong, Richie ^a   Salto Tellez, Manuel ^a,c  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Molecular pathology; Tissue microarrays; Translational research

Indexed keywords

BETA ACTIN; BIOLOGICAL MARKER;

DNA DETERMINATION; EMBEDDING; GENE SEQUENCE; HOSPITAL; MEDICAL RESEARCH; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; TISSUE MICROARRAY;

EID: 46749139206     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020802198101     Document Type: Article

References (57)

1. Crawford JM, Tykocinski ML. Pathology as the enabler of human research. Lab Invest 2005; 85: 1058-64.
2. Kajdacsy-Balla A, Geynisman JM, Macias V, et al. Cooperative Prostate Cancer Tissue Resource. Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol 2007; 38: 113-21.
3. Sinard JH, Morrow JS. Informatics and anatomic pathology: meeting the challenges and charting the future. Hum Pathol 2001; 32: 143-8.
4. Drake TA, Braun J, Marchevsky A, et al. A system for sharing routine surgical pathology specimens across institutions: the Shared Pathology Informatics Network. Hum Pathol 2007; 38: 1212-25.
5. Mohanty SK, Parwani AV, Crowley RS, et al. The importance of pathology informatics in translational research. Adv Anat Pathol 2007; 14: 320-2.
6. Zhang DH, Salto-Tellez M, Chiu LL, et al. Tissue microarray study for classification of breast tumors. Life Sciences 2003; 73: 3189-99.
7. Battifora H. The multitumor (sausage) tissue block: novel method for immuno-histochemical antibody testing. Lab Invest 1986; 55: 244-8.
8. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
9. Eguiluz C, Viguera E, Millan L, et al. Multitissue array review: a chronological description of tissue array techniques, applications and procedures. Pathol Res Pract 2006; 202: 561-8.
10. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001; 81: 1331-8.
11. Manley S, Mucci NR, De Marzo AM, et al. Rubin relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome. Am J Pathol 2001; 159: 837-43.
12. Takikita C, Chung JY, Hewitt SM. Tissue microarrays enabling high-throughput molecular pathology. Curr Opin Biotech 2007; 18: 318-25.
13. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
14. Mousses S, Bubendorf L, Wagner U, et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res 2002; 62: 1256-60.
15. Ito K, Liu Q, Salto-Tellez M, et al. Frequent cytoplasmic retention of RUNX3 in gastric cancer cells: A novel mechanism of inactivation. Cancer Res 2005; 65: 7743-50.
16. Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005; 12: 395-404.
17. Makretsov NA, Huntsman DG, Nielsen TO, et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004; 10: 6143-51.
18. Jacquemier J, Ginestier C, Rougemont J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005; 65: 767-79.
19. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discov 2003; 2: 962-72.
20. Horvath L, Henshall S. Timely Topic: The application of tissue microarrays to cancer research. Pathology 2001; 33: 125-9.
21. Zhang DH, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003; 16: 79-84.
22. Shibata D, Martin WJ, Arnheim N. Analysis of DNA sequences in forty-year old paraffin-embedded thin-tissue sections: a bridge between molecular biology and classical histology. Cancer Res 1988; 48: 4564-6.
23. Zhuang Z, Bertheau P, Emmert-Buck MR, et al. A microdissection technique for archival DNA analysis if specific cell populations in lesions <1 mm in size. Am J Pathol 1995; 146: 620-5.
24. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996; 274: 998-1001.
25. Rubin MA. Tech.Sight. Understanding disease cell by cell. Science 2002; 296: 1329-30.
26. Prince ME, Ubell ML, Castro J, et al. Tissue preserving approach to extracting DNA from paraffin-embedding specimens using tissue microarray technology. Head Neck 2007; 29: 465-71.
27. Coombs NJ, Gough AC, Primrose JN. Optimisation of DNA and RNA extraction from archival formalin-fixed tissue. Nucleic Acids Res 1999; 27: e12-7.
28. Shi SR, Cote RJ, Wu L, et al. DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J Histochem Cytochem 2002; 50: 1005-11.
29. Tos-Gillo A, Marco LD, Fiano V, et al. Efficient DNA extraction from 25 year old paraffin-embedded tissues: studies of 365 samples. Pathology 2007; 39: 345-8.
30. Sjoholm MIL, Hoffmann G, Lindgren S, et al. Comparison of archival plasma and formalin-fixed paraffin-embedded tissue for genotyping in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2005; 14: 251-5.
31. Mc Sherry EA, McGoldrick A, Kay EW, et al. Formalin fixed paraffin embedded clinical tissues show spurious copy number changes in array-CGH profiles. Clin Genet 2007; 72: 441-7.
32. Rupp GM, Locker J. Purification and analysis of RNA from paraffin-embedded tissues. Biotechniques 1988; 6: 56-60.
33. Finke J, Fritzen R, Temes P, et al. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. Biotechniques 1993; 14: 448-53.
34. Stanta G, Bonin S. RNA quantitative analysis from fixed and paraffin-embedded tissues: membrane hybridization and capillary electrophoresis. Biotechniques 1998; 24: 271-6.
35. Godfrey TE, Kim SH, Chavira M, et al. Quantitative mRNA expression analysis from formalin-fixed paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn 2000; 2: 84-91.
36. Specht K, Richter T, Muller U, et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumour tissue. Am J Pathol 2001; 158: 419-29.
37. Coudry RA, Meireles SI, Stoyanova R, et al. Successful application of microarray technology to microdissected formalin-fixed, paraffin-embedded tissue. J Mol Diagn 2007; 9: 70-9.
38. Tsuji S, Hisaoka M, Morimitsu Y, et al. Detection of SYT-SSX fusion transcripts in synovial sarcoma by reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. Am J Pathol 1998; 153: 1807-12.
39. Tvrdik D, Povysil C, Svatosova J, et al. Molecular diagnosis of synovial sarcoma: RT-PCR detection of SYT-SSX1/2 fusion transcripts in paraffin-embedded tissue. Med Sci Monit 2005; 11: MT1-7.
40. Aziz MH, Manoharan HT, Church DR, et al. Protein kinase Ce interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3ser727 and regulates its constitutive activation in prostate cancer. Cancer Res 2007; 67: 8828-38.
41. Mansilla F, Birkenkamp-Demtroder K, Kruhoffer M, et al. Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups. Br J Cancer 2007; 96: 1896-903.
42. Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y, Chapelle de la A. CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray based study. Thyroid 2004; 14: 169-75.
43. Ito Y, Miyazono K. RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev 2003; 132: 43-7.
44. Blyth K, Cameron ER, Neil JC. The RUNX Genes: gain or loss of function in cancer. Nat Rev Cancer 2005; 5: 76-87.
45. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113-24.
46. Lau QC, Raja E, Salto-Tellez M, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 2006; 66: 6512-20.
47. Chen W, Salto-Tellez M, Palanisamy N, et al. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics. Genes Chromosomes Cancer 2007; 46: 288-301.
48. Gurrieri C, Capodieci P, Bernardi R, et al. Loss of tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 2004; 96: 269-79.
49. Shi T, Seligson D, Belldegrun AS, et al. Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol 2005; 18: 547-57.
50. Duxbury MS, Matros E, Clancy T, et al. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and panIN lesions. Ann Surg 2005; 241: 491-6.
51. Salto-Tellez M, Peh BK, Ito K, et al. Runx3 protein is overexpressed in human basal cell carcinomas. Oncogene 2006; 25: 7646-9.
52. Salto-Tellez M, Nga ME, Han HC, et al. Tissue microarrays characterize the clinical significance of a VEGF-A protein expression signature in gastro-intestinal stromal tumors. Br J Cancer 2007; 96: 776-82.
53. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
54. Marx J. Medicine: Cancer-suppressing enzyme adds a link to type 2 diabetes. Science 2005; 310: 1259.
55. Waltz E. Informed consent issues hobble cancer genome scheme. Nat Med 2006; 12: 719.
56. Waltz E. Pricey cancer genome project struggles with sample shortage. Nat Med 2007; 13: 391.
57. Salto-Tellez M. A case for integrated morphomolecular pathologists. Clin Chem 2007; 53: 1188-90.